Legal & General Group Plc maintained its stake in shares of China Biologic Products, Inc. (NASDAQ:CBPO) during the first quarter, Holdings Channel reports. The institutional investor owned 2,101 shares of the biopharmaceutical company’s stock at the end of the first quarter. Legal & General Group Plc’s holdings in China Biologic Products were worth $210,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Eqis Capital Management Inc. increased its stake in shares of China Biologic Products by 51.3% in the first quarter. Eqis Capital Management Inc. now owns 3,220 shares of the biopharmaceutical company’s stock worth $322,000 after buying an additional 1,092 shares in the last quarter. Gateway Advisory LLC purchased a new stake in shares of China Biologic Products during the first quarter worth approximately $480,000. First Trust Advisors LP increased its stake in shares of China Biologic Products by 35.9% in the first quarter. First Trust Advisors LP now owns 11,561 shares of the biopharmaceutical company’s stock worth $1,158,000 after buying an additional 3,053 shares in the last quarter. Nordea Investment Management AB increased its stake in shares of China Biologic Products by 15.5% in the first quarter. Nordea Investment Management AB now owns 13,200 shares of the biopharmaceutical company’s stock worth $1,322,000 after buying an additional 1,768 shares in the last quarter. Finally, Oxford Asset Management purchased a new stake in shares of China Biologic Products during the first quarter worth approximately $1,453,000. Institutional investors own 74.09% of the company’s stock.

Shares of China Biologic Products, Inc. (NASDAQ:CBPO) traded up 0.37% during trading on Friday, hitting $91.51. The stock had a trading volume of 206,663 shares. The stock has a market capitalization of $2.49 billion, a P/E ratio of 23.82 and a beta of 1.70. China Biologic Products, Inc. has a 12-month low of $90.32 and a 12-month high of $126.47. The stock’s 50-day moving average is $102.40 and its 200-day moving average is $107.46.

China Biologic Products (NASDAQ:CBPO) last announced its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported $1.35 EPS for the quarter, beating the consensus estimate of $1.30 by $0.05. China Biologic Products had a net margin of 31.55% and a return on equity of 21.86%. The business had revenue of $89.28 million during the quarter, compared to the consensus estimate of $97.33 million. During the same period in the previous year, the business earned $1.26 earnings per share. The company’s revenue was down 2.3% on a year-over-year basis. Analysts predict that China Biologic Products, Inc. will post $4.96 EPS for the current fiscal year.

WARNING: “Legal & General Group Plc Continues to Hold Position in China Biologic Products, Inc. (NASDAQ:CBPO)” was posted by Watch List News and is owned by of Watch List News. If you are accessing this article on another domain, it was illegally copied and republished in violation of international trademark & copyright law. The legal version of this article can be accessed at https://www.watchlistnews.com/legal-general-group-plc-continues-to-hold-position-in-china-biologic-products-inc-nasdaqcbpo/1478883.html.

A number of analysts have commented on the company. Jefferies Group LLC reiterated a “buy” rating on shares of China Biologic Products in a research report on Friday, August 4th. Zacks Investment Research cut China Biologic Products from a “hold” rating to a “sell” rating in a report on Monday, August 7th. BidaskClub cut China Biologic Products from a “sell” rating to a “strong sell” rating in a report on Saturday, August 5th. Finally, Goldman Sachs Group, Inc. (The) started coverage on China Biologic Products in a report on Tuesday, May 30th. They issued a “neutral” rating for the company. Two analysts have rated the stock with a sell rating, one has issued a hold rating and two have given a buy rating to the company’s stock. China Biologic Products presently has an average rating of “Hold” and an average price target of $132.00.

About China Biologic Products

Want to see what other hedge funds are holding CBPO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for China Biologic Products, Inc. (NASDAQ:CBPO).

Institutional Ownership by Quarter for China Biologic Products (NASDAQ:CBPO)

Receive News & Ratings for China Biologic Products Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.